Wednesday 6-18-2014 Acadia Pharmaceuticals Inc (ACAD) $ACAD opened at 23.19 hitting the high price of 23.70 and a day low of 22.85 with a total volume of 658,794. ACAD had a previous close of 23.22 and has been seeing an average volume of 996,900.
Overall Average: 64% Buy
Recent stock forum discussions about ACAD http://investorshangout.com/search?q=ACAD&...mp;yt0=Go!
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
Business Wire - Tue Jun 17, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City. (full story)
Critical Alerts For JPMorgan, Darden Restaurants, BorgWarner, Acadia, and AFLAC Released By InvestorsObserver
PR Newswire - Fri May 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, DRI, BWA, ACAD, and AFL. (full story)
10.5% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu May 29, 5:05PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 10.47% as of today's recent price of $21.25. (full story)
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
Business Wire - Tue May 27, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City. (full story)
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 17.3% (ACAD)
Comtex SmarTrend(R) - Thu May 22, 11:05AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 17.34% as of today's recent price of $19.62. (full story)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Acadia Pharmaceuticals Is Down 0.6% (ACAD)
Comtex SmarTrend(R) - Mon May 19, 11:55AM CDT
When Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings a week ago on May 6th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $400.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.19 per share on sales of $30.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Acadia Pharmaceuticals have fallen from $19.16 to $19.05, representing a loss of 0.6% in the past 13 days. (full story)
Technical Coverage of Health Care Sector Equities -- Research on Intercept Pharma, ACADIA Pharma, DENTSPLY Intl., and OraSure Technologies
PR Newswire - Thu May 15, 10:42AM CDT
On Wednesday, May 14, 2014, the NASDAQ Composite ended at 4,100.63, down 0.72%, the Dow Jones Industrial Average finished the day 0.61% lower at 16,613.97, and the S&P 500 closed at 1,888.53, down 0.47%. During the session, five out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 676.57, up 0.03%, with the index also advancing 4.40% in the last one month. Investor-Edge has initiated coverage on the following equities: Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), DENTSPLY International Inc. (NASDAQ: XRAY) and OraSure Technologies Inc. (NASDAQ: OSUR). Free technical research on ICPT, ACAD, XRAY and OSUR can be downloaded upon signing up at: (full story)
Shares of ACAD Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:39AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 15.74% as of today's recent price of $20.00. (full story)
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free. (full story)
Acadia Pharmaceuticals Has Returned 20.4% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Thu May 08, 9:12AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 1 month, Acadia Pharmaceuticals has returned 20.37% as of today's recent price of $18.90. (full story)
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia (full story)
Alzheimer's Disease - Pipeline Review, H1 2014: 208 Companies Profiled
M2 - Thu May 08, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x458ps/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AB Science - AC Immune SA - ALSP, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Accera, Inc. - Acumen Pharmaceuticals, Inc. - AdAlta Pty Ltd. - Addex Therapeutics - Affichem - Allinky Biopharma - AlzProtect SAS - AlzeCure Discovery AB - Alzhyme Ltd. - Alzinova AB - Amgen Inc. - Anavex Life Sciences Corp. - Angita B.V. - Aphios Corporation - Apodemus AB - Applied NeuroSolutions, Inc. - Archer Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Avanir Pharmaceuticals, Inc. - Avergen Ltd - Avineuro Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/x458ps/alzheimers (full story)
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain (full story)
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 3:02PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2014. (full story)
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Thu May 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: (full story)
Acadia Pharmaceuticals Down 15.2% Since SmarTrend Downtrend Call (ACAD)
Comtex SmarTrend(R) - Wed Apr 30, 4:51PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 1 month, Acadia Pharmaceuticals has returned 15.19% as of today's recent price of $20.13. (full story)
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
Business Wire - Tue Apr 29, 8:02AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2014 on Tuesday, May 6, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, May 6, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs. (full story)
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst. (full story)
Overall Average: 64% Buy
Recent stock forum discussions about ACAD http://investorshangout.com/search?q=ACAD&...mp;yt0=Go!
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
Business Wire - Tue Jun 17, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City. (full story)
Critical Alerts For JPMorgan, Darden Restaurants, BorgWarner, Acadia, and AFLAC Released By InvestorsObserver
PR Newswire - Fri May 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, DRI, BWA, ACAD, and AFL. (full story)
10.5% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu May 29, 5:05PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 10.47% as of today's recent price of $21.25. (full story)
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
Business Wire - Tue May 27, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City. (full story)
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 17.3% (ACAD)
Comtex SmarTrend(R) - Thu May 22, 11:05AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 17.34% as of today's recent price of $19.62. (full story)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Acadia Pharmaceuticals Is Down 0.6% (ACAD)
Comtex SmarTrend(R) - Mon May 19, 11:55AM CDT
When Acadia Pharmaceuticals (NASDAQ:ACAD) reported earnings a week ago on May 6th, 2014, analysts, on average, expected the company to report a loss of $0.13 on sales of $400.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.19 per share on sales of $30.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Since the company's report, shares of Acadia Pharmaceuticals have fallen from $19.16 to $19.05, representing a loss of 0.6% in the past 13 days. (full story)
Technical Coverage of Health Care Sector Equities -- Research on Intercept Pharma, ACADIA Pharma, DENTSPLY Intl., and OraSure Technologies
PR Newswire - Thu May 15, 10:42AM CDT
On Wednesday, May 14, 2014, the NASDAQ Composite ended at 4,100.63, down 0.72%, the Dow Jones Industrial Average finished the day 0.61% lower at 16,613.97, and the S&P 500 closed at 1,888.53, down 0.47%. During the session, five out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 676.57, up 0.03%, with the index also advancing 4.40% in the last one month. Investor-Edge has initiated coverage on the following equities: Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), DENTSPLY International Inc. (NASDAQ: XRAY) and OraSure Technologies Inc. (NASDAQ: OSUR). Free technical research on ICPT, ACAD, XRAY and OSUR can be downloaded upon signing up at: (full story)
Shares of ACAD Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:39AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 15.74% as of today's recent price of $20.00. (full story)
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free. (full story)
Acadia Pharmaceuticals Has Returned 20.4% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Thu May 08, 9:12AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 1 month, Acadia Pharmaceuticals has returned 20.37% as of today's recent price of $18.90. (full story)
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia (full story)
Alzheimer's Disease - Pipeline Review, H1 2014: 208 Companies Profiled
M2 - Thu May 08, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x458ps/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AB Science - AC Immune SA - ALSP, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Accera, Inc. - Acumen Pharmaceuticals, Inc. - AdAlta Pty Ltd. - Addex Therapeutics - Affichem - Allinky Biopharma - AlzProtect SAS - AlzeCure Discovery AB - Alzhyme Ltd. - Alzinova AB - Amgen Inc. - Anavex Life Sciences Corp. - Angita B.V. - Aphios Corporation - Apodemus AB - Applied NeuroSolutions, Inc. - Archer Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Avanir Pharmaceuticals, Inc. - Avergen Ltd - Avineuro Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/x458ps/alzheimers (full story)
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain (full story)
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue May 06, 3:02PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2014. (full story)
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Thu May 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: (full story)
Acadia Pharmaceuticals Down 15.2% Since SmarTrend Downtrend Call (ACAD)
Comtex SmarTrend(R) - Wed Apr 30, 4:51PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 1 month, Acadia Pharmaceuticals has returned 15.19% as of today's recent price of $20.13. (full story)
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
Business Wire - Tue Apr 29, 8:02AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2014 on Tuesday, May 6, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, May 6, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs. (full story)
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst. (full story)
